Fertility Test Market Size, Share & Trends Analysis Report By Product (Ovulation Prediction Kits, Fertility Monitors, Urine-based Ovulation Test Kits, Saliva-based Ovulation Test Kits, Male Fertility Test Kits), By Mode of Purchase (OTC-based, Prescription-based), By Application (Female Fertility Testing, Male Fertility Testing), By End User (Home Care Settings, Fertility Clinics) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Fertility Test Market Size

The global fertility test market size was valued at USD 629.43 million in 2024 and is expected to grow from USD 680.42 million in 2025 to USD 1,268.77 million by 2033, growing at a CAGR of 8.1% during the forecast period (2025-2033).

The medical and physical examination known as "fertility testing" determines whether or not an individual is naturally capable of conceiving children and carrying them to term. On the other hand, because getting older is one of the factors that can affect fertility, women and men who are 35 or older and have been trying to conceive for at least six months but have not been successful should consider getting fertility testing if they cannot have children despite their best efforts.

The process of determining a person's fertility begins with a conversation about their medical history, followed by blood tests and procedures that are only minimally invasive. It primarily involves the ovulation test, which detects hormones such as luteinizing or progesterone in the patient's blood, urine, or saliva. The men's testing includes examining the sperm sample to determine whether it has an average count.

This increase in market size can be attributed to the rise in the prevalence of diseases such as polycystic ovary syndrome (PCOS). Women with PCOS do not regularly ovulate each month due to the overproduction of estrogen by the ovaries. The growth of the market is also being driven by a rise in the number of women experiencing their first pregnancy, as well as a general decrease in the number of children born per woman around the world. In addition, expanding consumer knowledge concerning fertility testing in developed and developing countries is a driving force behind the market expansion. In today's world, many businesses and nonprofit organizations hold yearly events and camps to educate people about the importance of fertility testing. Additionally, the introduction of technologically advanced products and shifts in lifestyle can lead to increased market growth for fertility tests.

Fertility Test Market Growth Factors

Rise of consumer awareness regarding fertility testing to drive market

Infertility can be a confusing and incredibly isolating experience for people going through it. According to the National Infertility Association (NIA), National Infertility Awareness Week is a celebration that takes place once every year. It brings together millions of people who share a common goal of eradicating the stereotypes and obstacles that stand in the way of people starting families. It assists the community with the problems they are experiencing regarding their fertility. This contributes to increasing people's awareness of the importance of fertility testing. For instance, IVF Babble organized an annual event to raise awareness about Infertility and fertility testing in the United States. It prioritizes assisting individuals with difficulties conceiving by providing them with trustworthy resources and networks to lean on during difficult times.

Growing use of technologically advanced products to impede market growth

The recent introduction of products for fertility testing with a high accuracy level has the potential to drive growth in the market for fertility tests. For example, Modern Fertility introduced a pregnancy and ovulation test kit. Additionally, the company launched a dedicated app for it to consolidate all of the data about fertility. The app assists in reading and keeping track of test results, and it is part of a more significant push by the company to bring the fertility category into the realm of mainstream wellness. Similarly, the Food and Drug Administration (FDA) approved the company Prov for the at-home ovulation testing kit it manufactures. PdG, a progesterone metabolite, is detected in a woman's urine using this test. Progesterone is a hormone produced in a woman's ovary after ovulation. The most recent version of the OvuSense app, known as OvuSense app V.2, was released by Fertility Focus Limited. This version offers improved adaptability regarding the data and a greater variety of options for logging events than most other apps and enhanced precision in monitoring cycles. It is anticipated that introducing such innovative and practical products will drive market expansion for fertility tests.

Declining fertility rates among men and women

Fertility rates have dropped 50% overall during the past 70 years globally. Women's empowerment in the workforce and school decreased infant mortality, and rising child-rearing expenses are some of the causes. An aging population is exerting pressure on healthcare systems worldwide due to lower birth rates and longer life expectancies, resulting in the market's expansion.

Market Restraining Factors

Ovulation monitors in patients with pcos and pcod to restrict market growth

Ovulation monitors are instruments that women use to ascertain the point in their menstrual cycles when the likelihood of becoming pregnant is at its highest. The test looks for an increase in luteinizing hormone (LH) in the urine because an increase in this hormone causes the ovary to release an egg when pregnancy is present. Ovulation monitors, when used correctly, have the potential to deliver an accuracy of 99 percent in identifying the LH surge that comes before ovulation. The Polycystic Ovary Syndrome Awareness Association (PCOSAA) estimates that approximately 5 million women in the United States suffer from polycystic ovarian syndrome. In patients with polycystic ovary syndrome (PCOS), the level of luteinizing hormone or the level of estrogen hormone is consistently high, and in some cases, multiple peaks can be seen. As a result, the ovulation test kit may not provide accurate results. As a result, the findings may give a false indication of whether or not the female has ovulated. The ovulation prediction test cannot be considered accurate in determining whether the woman has ovulated in these circumstances. This factor can potentially impede the market's expansion of fertility tests.

Lack of awareness

A significant obstacle for the fertility test market is that many underdeveloped areas need to learn how to use ovulation kits and understand their advantages. In the upcoming years, the major market participants and drivers for ovulation tests will overcome these difficulties.

Lack of accuracy in test procedures

The ovulation test only picks up the luteinizing chemicals that lead to ovulation; it cannot confirm ovulation. Ovulation tests will not be accurate if the person has used medications. Ovulation tests are also ineffective in those over the age of 40 and in PCOS/PCOD patients. These elements may function as growth inhibitors for the ovulation test industry.

Market Opportunities

Growing sales of fertility testing devices via online platforms to boost market opportunities

The fertility testing equipment is available at the local pharmacies and is not difficult to acquire. These instruments can be purchased "over the counter," indicating that a doctor's authorization is unnecessary to receive them. The marketing of these products in online retail establishments is consequently simplified. Several online stores, including Amazon, Flipkart, and Walmart, have these products for sale. The market participants are also putting into action strategies to sell fertility testing devices online on the company websites of each of the respective companies. They have launched their e-commerce website for their customers to purchase their products. For instance, the company Modern Fertility recently started selling its products on its very own e-commerce website. It is anticipated that implementing these kinds of strategies will produce abundant opportunities to expand the fertility test market.

Evolving lifestyle

People's lifestyles are evolving, and nations are experiencing economic growth. The market for fertility tests will have more potential as people's per capita income rises and ovulation and pregnancy test kits become more widely used. People used to need to visit the hospital for an ovulation test. Since technology has advanced, people can now test in the convenience of their own homes. Therefore, the market for fertility tests will have additional chances as digital technology is increasingly adopted.

Regional Insights

Asia-Pacific is the highest revenue contributor, growing a CAGR of 8.7% during the forecast period. The rise in the number of people affected by diseases like PCOS and PCOD is mainly responsible for expanding this region's market. In addition, the market's growth is fueled by an increase in the demand for fertility test products and testing devices at home. A rise in the prevalence of infertility and PCOS/PCOD, the availability of technologically advanced products, an increase in the awareness of fertility testing, and a rise in the demand for an advanced fertility test are all factors that have contributed to this rise. In addition, falling fertility rates and an increase in the number of women experiencing their first pregnancy are the primary contributors to the significant growth of the market. The expansion of leading manufacturers' efforts to broaden their geographical presence in developing Asia-Pacific nations to capitalize on countries with high growth opportunities is another factor contributing to the development of the market.

Europe: Fastest growing region with a CAGR of 8.2%

Europe is the second-largest contributor to the market and is estimated to reach around USD 305.09 million at a CAGR of 8.2% during the forecast period. The availability of technologically advanced products, an increase in demand for advanced fertility tests, and the strong presence of key players such as Fertility Focus Limited, Geratherm Medical AG, and Swiss Precision Diagnostics GmbH are expected to drive growth in the fertility test industry in European countries at a consistent rate throughout the forecast period. This is expected to drive growth in the fertility test market in European countries. The rise in the use of fertility tests by couples in European countries, as well as the ongoing efforts made by the Fertility Europe Association (FEA) to raise public awareness about infertility and fertility testing, are also factors that contribute to the expansion of the market. In addition, the key growth drivers in Europe are new product innovations in the pharmaceutical and medical device industries and an increase in the prevalence of diseases such as PCOS and PCOD. In addition, the existence of an already developed infrastructure in the medical sector is anticipated to propel the European market's expansion further.

North America is the third-largest contributor to the market. It is owing to factors such as an increase in the prevalence of diseases such as infertility and PCOS/PCOD, growth in the awareness regarding fertility testing among the population, an increase in the number of women becoming pregnant for the first time, easy availability of technologically advanced products, and the introduction of new products with a high level of accuracy. The presence of major key players in the region, such as Church & Dwight Co., Inc., Fairhaven Health LLC, Hilin Life Products Inc, Prestige Consumer Healthcare Inc., Quidel Corporation, Abbott Laboratories, and AdvaCare Pharma, is a significant factor that contributes toward the growth of the fertility test market. This factor is an essential factor contributing to the development of the fertility test industry. A rise in the demand for fertility testing products, an increase in the prevalence of infertility and PCOS/PCOD, the availability of technologically advanced products, and a rise in awareness regarding fertility testing all contribute significantly to the expansion of the market in North America.

Growth in patient awareness regarding fertility testing is a critical factor that is anticipated to drive the expansion of the market in LAMEA. The Latin American, Caribbean, and Middle Eastern Area (LAMEA) region is a developing market that is anticipated to provide lucrative growth opportunities for key players. This is because of an increase in the number of people who are the market's target demographic, a surge in demand for fertility tests, and the introduction of new products for fertility testing.

Product Insights

The ovulation prediction kits were the highest contributor to the market, growing at a CAGR of 7.9% during the forecast period. Due to recent technological advancements, ovulation test kit manufacturers now have access to many new market opportunities. Manufacturers have been developing proprietary technology platforms to differentiate themselves from their rivals and capitalize on these opportunities. In addition, they have developed cost-effective and proprietary solutions protected by patents to remain competitive and preserve their positions in the market for fertility tests.

The second-largest segment is the fertility monitors segment which is expected to reach around USD 331.70 million by 2030 at a CAGR of 8.8% during the forecast period. It is anticipated that factors such as an increase in the prevalence of diseases such as PCOS, an increase in the number of first-time pregnancies in women, a decline in fertility rates across the globe, a growth in awareness regarding fertility testing in both developed and developing countries, and the launch of technologically advanced products with a high level of accuracy will drive the development of the fertility test market. In addition, an increasing preference for the confidentiality and accessibility of test results and the rapid outcomes of diagnosis are also driving forces behind the expansion of the market segment.

Mode Of Purchase Insights

The OTC-based fertility tests segment was the highest contributor to the market, growing at a CAGR of 8.3% during the forecast period. Due to several factors, including an increase in the prevalence of conditions like PCOS, an increase in the number of first-time pregnancies among women, a global decline in fertility rates, a rise in awareness of fertility testing in both developed and developing nations and the introduction of technologically advanced products with a high level of accuracy, the market has seen a growth.

The prescription-based segment is the second-largest segment and is estimated to grow at a CAGR of 6.9% during the forecast period. If the patient is ovulating, then the patient's progesterone level should be rising, and if it is not, then it is likely that the patient is not ovulating. If the progesterone level is not growing, then it is expected that the patient is not ovulating. In contrast to the over-the-counter fertility test, this one determines whether or not ovulation has taken place, as opposed to making an educated guess as to when the patient is most likely to release an egg. It is one of the tests that can help medical professionals determine whether the patient has any fertility issues.

Application Insights

The female fertility testing segment was the highest contributor to the market, growing at a CAGR of 8.3% during the forecast period. A rise in the prevalence of diseases such as PCOS increases in first-time pregnancies in women, a decline in fertility rates across the globe, a surge in awareness of fertility testing in both developed and developing countries and the launch of technologically advanced products with high accuracy are all factors that have contributed to this rise.

The male fertility testing segment is the second-largest segment and is estimated to grow at a CAGR of 7.4% by 2030. It is a process that involves testing the sperm to determine whether or not it has the necessary sperm count to be fertile. Sperm should have a count of at least 20 million per milliliter, as anything lower than that is indicative of male infertility. During this process, the number of sperm, their shape, and how quickly they move are evaluated.

End-User Insights

The home care setting segment was the highest contributor to the market, growing at a CAGR of 8.4% during the forecast period. Since they offer a high level of convenience and because they have a significant presence in home care settings all over the world. The patients in this vulnerable population undergoing fertility treatment as part of continuous care are more likely to feel supported and understood, including communication between the patient and the provider. As a result of these factors, it is believed that the home care setting will present a significant opportunity for growth in the fertility test market throughout the anticipated period.

The Hospitals/fertility clinics testing segment is the second-largest segment and is estimated to grow at a CAGR of 7.5% during the forecast period. To raise the patient's chances of becoming pregnant, fertility clinics offer services that increase the likelihood of ovulation induction. For women unable to ovulate regularly, oral or injectable medications are available from fertility clinics to support oocyte development. Rising infertility rates among the populace may impact the expansion of the global market within the confines of fertility clinics.

Recent Developments

• In September 2022, Church & Dwight paid $630 million to acquire Hero, the company behind the Mighty Patch® Brand.
• In December 2022, Quidel TriageTrue® High-Sensitivity Troponin I Test was Granted License by Health Canada to Help Diagnose Myocardial Infarction
• In December 2022, To Develop and Produce Assays for the VITROS® Platform, QuidelOrtho and Runda Medical formed a Joint Venture.
• In February 2023, Abbott announced two approvals today as part of its expanding line of electrophysiological products on the global market. The business's TactiFlexTM Ablation Catheter, Sensor EnabledTM, the only ablation catheter in the world with a flexible tip and contact force sensing, has been granted CE Mark1 to treat persons with irregular heart rhythms such as atrial fibrillation (AFib). The U.S. Food and Drug Administration recently granted an additional indication2 for using Abbott's FlexAbilityTM Ablation Catheter, Sensor EnabledTM, to treat patients with complicated cardiac conditions (FDA).